Publications

Key Published Literature

Anti-Factor VIII

Dewerchin M, Van der Elst L, Singh I, et al. Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice. J Thromb Haemost. 2004;2(1):77-84. http://www.ncbi.nlm.nih.gov/pubmed/14717970

Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95(1):156-163. http://www.ncbi.nlm.nih.gov/pubmed/10607698

Jacquemin M, Radcliffe CM, Lavend’homme R, et al. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost. 2006;4(5):1047-1055. http://www.ncbi.nlm.nih.gov/pubmed/16689758

Jacquemin M, Saint-Remy JM. The use of antibodies to coagulation factors for anticoagulant therapy. Curr Med Chem. 2004;11(17):2291-2296. http://www.ncbi.nlm.nih.gov/pubmed/15379713

Jacquemin M, Stassen JM, Saint-Remy JM, et al. A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons. J Thromb Haemost. 2009;7(3):429-437. http://www.ncbi.nlm.nih.gov/pubmed/19207364

Jacquemin M. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. Haemophilia. 2010;16(102):16-19. http://www.ncbi.nlm.nih.gov/pubmed/20536982

Singh I, Smith A, Vanzieleghem B, et al. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood. 2002;99(9):3235-3240. http://www.ncbi.nlm.nih.gov/pubmed/11964288

Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun; 32(6): 1205-20. http://www.ncbi.nlm.nih.gov/pubmed/20637972